CD276 and anaplastic meningioma: presented the results of the first-in-human clinical study on B7-H3-targeted CAR T cells for the treatment of recurrent anaplastic meningioma and provided evidence that the local delivery of B7-H3-targeted CAR T cells could suppress tumor progression without off-tumor toxicity or serious side effects, thus indicating the tolerability, safety, and potential efficacy of this therapy (94).